Veeva Systems Valuation
Is VEEV * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VEEV * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VEEV * (MX$3509.95) is trading below our estimate of fair value (MX$3558.88)
Significantly Below Fair Value: VEEV * is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VEEV *?
Other financial metrics that can be useful for relative valuation.
| What is VEEV *'s n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$33.98b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 12.7x |
| Enterprise Value/EBITDA | 65x |
| PEG Ratio | 3.9x |
Price to Earnings Ratio vs Peers
How does VEEV *'s PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 85.6x | ||
2413 M3 | 24.2x | 12.0% | JP¥1.1t |
PME Pro Medicus | 175.1x | 20.3% | AU$12.2b |
SECT B Sectra | 107.5x | 15.7% | kr45.6b |
DOCS Doximity | 35.4x | 9.6% | US$5.2b |
VEEV * Veeva Systems | 64.6x | 16.7% | Mex$34.0b |
Price-To-Earnings vs Peers: VEEV * is good value based on its Price-To-Earnings Ratio (64.6x) compared to the peer average (85.6x).
Price to Earnings Ratio vs Industry
How does VEEV *'s PE Ratio compare vs other companies in the Global Healthcare Services Industry?
Price-To-Earnings vs Industry: VEEV * is expensive based on its Price-To-Earnings Ratio (64.6x) compared to the Global Healthcare Services industry average (26.6x).
Price to Earnings Ratio vs Fair Ratio
What is VEEV *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 64.6x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate VEEV *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$3,509.95 | Mex$4,073.07 +16.0% | 8.2% | Mex$4,547.77 | Mex$3,368.72 | n/a | 26 |
| May ’25 | n/a | Mex$4,123.40 0% | 8.0% | Mex$4,604.12 | Mex$3,410.46 | n/a | 27 |
| Apr ’25 | n/a | Mex$4,048.42 0% | 8.1% | Mex$4,535.68 | Mex$3,359.76 | n/a | 28 |
| Mar ’25 | Mex$3,726.81 | Mex$3,956.84 +6.2% | 11.0% | Mex$4,595.02 | Mex$2,722.98 | n/a | 28 |
| Feb ’25 | n/a | Mex$3,679.24 0% | 11.4% | Mex$4,602.04 | Mex$2,757.78 | n/a | 26 |
| Jan ’25 | n/a | Mex$3,597.10 0% | 11.0% | Mex$4,534.27 | Mex$2,717.17 | n/a | 27 |
| Dec ’24 | n/a | Mex$3,705.59 0% | 11.5% | Mex$4,574.24 | Mex$2,741.12 | n/a | 27 |
| Nov ’24 | n/a | Mex$4,164.93 0% | 9.2% | Mex$5,038.22 | Mex$3,316.06 | n/a | 27 |
| Oct ’24 | n/a | Mex$3,842.20 0% | 9.2% | Mex$4,695.19 | Mex$3,090.29 | n/a | 25 |
| Sep ’24 | Mex$3,227.00 | Mex$3,804.79 +17.9% | 9.0% | Mex$4,700.11 | Mex$3,093.53 | n/a | 26 |
| Aug ’24 | n/a | Mex$3,572.91 0% | 11.2% | Mex$4,587.39 | Mex$2,835.84 | n/a | 27 |
| Jul ’24 | n/a | Mex$3,641.40 0% | 11.1% | Mex$4,723.51 | Mex$2,919.99 | n/a | 26 |
| Jun ’24 | Mex$3,305.00 | Mex$3,682.16 +11.4% | 11.7% | Mex$4,827.19 | Mex$2,984.08 | n/a | 26 |
| May ’24 | Mex$3,296.31 | Mex$3,757.80 +14.0% | 11.1% | Mex$4,944.47 | Mex$3,056.58 | n/a | 25 |
| Apr ’24 | Mex$3,230.00 | Mex$3,771.73 +16.8% | 11.1% | Mex$4,956.16 | Mex$3,063.81 | n/a | 25 |
| Mar ’24 | n/a | Mex$3,749.88 0% | 10.1% | Mex$4,797.27 | Mex$3,077.49 | Mex$3,726.81 | 26 |
| Feb ’24 | Mex$3,227.24 | Mex$3,910.33 +21.2% | 10.2% | Mex$4,948.69 | Mex$3,174.63 | n/a | 27 |
| Jan ’24 | Mex$3,073.38 | Mex$4,101.05 +33.4% | 10.4% | Mex$5,131.06 | Mex$3,291.63 | n/a | 27 |
| Dec ’23 | Mex$3,681.97 | Mex$4,101.24 +11.4% | 9.9% | Mex$4,963.36 | Mex$3,283.16 | n/a | 25 |
| Nov ’23 | Mex$3,322.94 | Mex$4,207.79 +26.6% | 10.1% | Mex$5,092.30 | Mex$3,368.45 | n/a | 25 |
| Oct ’23 | n/a | Mex$4,412.76 0% | 10.2% | Mex$5,522.22 | Mex$3,714.95 | n/a | 24 |
| Sep ’23 | Mex$3,385.00 | Mex$4,469.36 +32.0% | 10.4% | Mex$5,551.15 | Mex$3,734.41 | Mex$3,227.00 | 22 |
| Aug ’23 | Mex$4,290.40 | Mex$4,728.29 +10.2% | 12.6% | Mex$5,628.92 | Mex$3,582.04 | n/a | 22 |
| Jul ’23 | Mex$4,003.00 | Mex$4,645.96 +16.1% | 13.3% | Mex$5,837.41 | Mex$3,522.58 | n/a | 21 |
| Jun ’23 | Mex$3,350.00 | Mex$4,808.69 +43.5% | 15.0% | Mex$5,911.05 | Mex$3,448.11 | Mex$3,305.00 | 19 |
| May ’23 | Mex$3,755.21 | Mex$5,075.56 +35.2% | 11.5% | Mex$5,932.86 | Mex$3,955.24 | Mex$3,296.31 | 20 |
Analyst Forecast: Target price is less than 20% higher than the current share price.